BioSig Technologies, Inc. (BSGM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BSGM POWR Grades
- BSGM scores best on the Growth dimension, with a Growth rank ahead of 85.92% of US stocks.
- The strongest trend for BSGM is in Momentum, which has been heading up over the past 54 days.
- BSGM's current lowest rank is in the Quality metric (where it is better than 0.61% of US stocks).
BSGM Stock Summary
- BSGM has a higher market value than just 7.02% of US stocks; more precisely, its current market capitalization is $18,343,818.
- BSGM's price/sales ratio is 115.37; that's higher than the P/S ratio of 97.76% of US stocks.
- Revenue growth over the past 12 months for BIOSIG TECHNOLOGIES INC comes in at -63.28%, a number that bests only 3.05% of the US stocks we're tracking.
- Stocks that are quantitatively similar to BSGM, based on their financial statements, market capitalization, and price volatility, are ONTF, YEXT, ETON, CSTL, and EVLV.
- Visit BSGM's SEC page to see the company's official filings. To visit the company's web site, go to www.biosig.com.
BSGM Valuation Summary
- In comparison to the median Healthcare stock, BSGM's price/sales ratio is 6095% higher, now standing at 123.9.
- Over the past 98 months, BSGM's EV/EBIT ratio has gone up 2.9.
Below are key valuation metrics over time for BSGM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BSGM | 2022-11-25 | 123.9 | 10.8 | -0.7 | -0.7 |
| BSGM | 2022-11-23 | 115.1 | 10.0 | -0.6 | -0.6 |
| BSGM | 2022-11-22 | 119.5 | 10.4 | -0.7 | -0.7 |
| BSGM | 2022-11-21 | 119.5 | 10.4 | -0.7 | -0.7 |
| BSGM | 2022-11-18 | 122.6 | 10.7 | -0.7 | -0.7 |
| BSGM | 2022-11-17 | 132.7 | 11.6 | -0.7 | -0.7 |
BSGM Growth Metrics
- The 3 year price growth rate now stands at -83.1%.
- Its 5 year net cashflow from operations growth rate is now at -250.52%.
- Its 4 year net income to common stockholders growth rate is now at -253.79%.
The table below shows BSGM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.159 | -23.322 | -28.872 |
| 2022-06-30 | 0.132 | -25.133 | -29.736 |
| 2022-03-31 | 0.331 | -25.349 | -31.57 |
| 2021-12-31 | 0.441 | -26.399 | -31.926 |
| 2021-09-30 | 0.433 | -26.77224 | -33.5746 |
| 2021-06-30 | 0.325 | -26.28766 | -37.72384 |
BSGM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BSGM has a Quality Grade of F, ranking ahead of 2.09% of graded US stocks.
- BSGM's asset turnover comes in at 0.012 -- ranking 168th of 186 Medical Equipment stocks.
- IDXG, CERS, and NVCR are the stocks whose asset turnover ratios are most correlated with BSGM.
The table below shows BSGM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.012 | 0.505 | -124.410 |
| 2021-03-31 | 0.004 | 0.161 | -37.903 |
| 2020-12-31 | 0.000 | NA | -21.740 |
| 2020-09-30 | 0.000 | NA | -22.716 |
| 2020-06-30 | 0.000 | NA | -20.310 |
| 2020-03-31 | 0.000 | NA | -17.440 |
BSGM Price Target
For more insight on analysts targets of BSGM, see our BSGM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
BSGM Stock Price Chart Interactive Chart >
BSGM Price/Volume Stats
| Current price | $0.42 | 52-week high | $3.10 |
| Prev. close | $0.41 | 52-week low | $0.25 |
| Day low | $0.38 | Volume | 295,500 |
| Day high | $0.46 | Avg. volume | 276,352 |
| 50-day MA | $0.55 | Dividend yield | N/A |
| 200-day MA | $0.87 | Market Cap | 19.89M |
BioSig Technologies, Inc. (BSGM) Company Bio
BioSig Technologies, Inc., a medical device company, engages in developing and commercializing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company's proprietary product include precise uninterrupted real-time evaluation of electrograms electrophysiology system, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures in an electrophysiology laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Westport, Connecticut.
Latest BSGM News From Around the Web
Below are the latest news stories about BIOSIG TECHNOLOGIES INC that investors may wish to consider to help them evaluate BSGM as an investment opportunity.
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CymaBay Therapeutics (CBAY – Research Report) and BioSig Technologies (BSGM – Research Report) with bullish sentiments. CymaBay Therapeutics (CBAY) In a report released today, Sean Kim PhD from JonesTrading maintained a Buy rating on CymaBay Therapeutics, with a price target of $8.00. The company's shares closed last Tuesday at $3.67. According to TipRanks. |
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing TechnologyWestport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology Clinical investigations conducted by Cleveland Clinic could expand clinical parameters of BioSig’s digital signal processing technology for arrhythmia care BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company deliver |
BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022Company to introduce its novel digital signal processing technology to the European EP community at world-renown international congressWestport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that it has been invited to attend the 17th Edition |
BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer BaseLeading medical center in San Antonio acquires BioSig’s novel digital signal processing technology for arrhythmia careWestport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that San Antonio Methodist Hospital has acquired the PURE EP™ System. |
BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ ModuleCompany to introduce the most advanced iteration of its signal processing technology at Cleveland Clinic’s Global EP Summit 2022, a world-class leadership symposiumWestport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE E |
BSGM Price Returns
| 1-mo | -17.71% |
| 3-mo | -61.82% |
| 6-mo | -54.35% |
| 1-year | -84.84% |
| 3-year | -93.81% |
| 5-year | -88.41% |
| YTD | -81.17% |
| 2021 | -42.82% |
| 2020 | -34.12% |
| 2019 | 38.64% |
| 2018 | 18.60% |
| 2017 | 11.63% |
Loading social stream, please wait...